Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review)
О. D. Gurieva, М. I. Savelyeva, Т. Т. Валиев
Abstract
Inspite of great successes in treatment and high incidence of surveillance in pediatric acute lymphoblastic leukemia (ALL), patients are addicted to many drugs adverse events, which sometimes indicate to decrease the dose or even cytotoxic drug interruption with following risk of secondary disease relapse. Besides, researches found significant inter-individual variability of drugs toxicity and disease outcome. This fact specify a role of pharmacogenetics (PGx) in genetic polymorphism revealing in gene-candidates for treatment optimization. Global wide initiated studies of correlation analysis between genetic polymorphism and toxicity effects of ALL treatment in different ethnic groups of patients. In Russia such studies are rare. In the current review we present annotations of gene-candidates of drugs with highest degree of proof their role in different types of clinical toxicity variants and recommendations for following PGx use in individualization of treatment protocols for pediatric ALL.